Evogliptin tartrate

CAS: 1222102-51-3 货号: E654501 分子式: C23H32F3N3O9 分子量: 401.4215009 PubChem CID: 135395528
有货
级别和纯度: 10mM in DMSO
别名
酒石酸依沃列汀
储存条件
干燥,-80℃储存
运输条件
特低温运输
★
规格
库存
价格
数量
1ml
E654501-1ml
期货 Stock Image
¥3,850.90
请输入您要添加的产品数量

概述


Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy . Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation

In Vitro

Evogliptin tartrate (2.49 mM; 12 h) efficiently inhibits mDPP4 (membrane DPP4) enzymatic activity in PWM-induced H9 Th1 cells. Evogliptin tartrate prevents inflammatory and fibrotic signaling through autophagy induction in primary hepatocytes of ATG7 f/f -Cre + mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: H9 Th1 cells (pokeweed mitogen (PWM)-induced) Concentration: 2.49 mM (1 µg/mL) Incubation Time: 12 h Result: Potently inhibited mDPP4 (membrane DPP4) activity in a dose-dependent manner but did not affect either the cytokine profile or cell viability in PWM-activated CD4 + CD26 + H9 Th1 cells.

In Vivo

Evogliptin tartrate (100, 300 mg/kg; in animal feedings; single daily for 10 weeks) exhibits antidiabetic effects on HFD/STZ mice and improves glucose intolerance and insulin resistance. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male ICR mice (four-week-old; HFD/STZ mice model). Dosage: 100, 300 mg/kg Administration: In animal feedings; single daily for 10 weeks Result: Decreased the blood glucose level from the second weekand persisted through the 10-week treatment, when at 300 mg/kg. Significantly reduced HbA1c level when dosage at 300 mg/kg. Significantly decreased 6 h-fasted blood glucose levels in a dose-dependent manner.

IC50& Target:DPP-4

规格

别名
酒石酸依沃列汀
规格或纯度
10mM in DMSO
英文名称
Evogliptin tartrate
生化机理
酒石酸埃沃格列汀(DA-1229)是一种口服活性 DPP4 抑制剂,在小鼠模型中具有显著和持续的降血糖作用。酒石酸埃沃格列汀还能通过诱导肝细胞自噬,抑制肝细胞中炎症和纤维化信号的产生。
储存条件
干燥,-80℃储存
运输条件
特低温运输
名称和识别符
分子类型
小分子
Isomeric SMILES
CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
PubChem CID
分子量
401.4215009

高级数据

质检证书(CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器

常见问题

本产品应如何储存?
请于?80 °C、干燥条件下保存。请与干燥剂一同密封保存,本品对湿气敏感。
本产品如何运输?
本产品采用干冰配冷袋冷冻运输。收货后请立即拆包,并按上述储存条件保存;处理干冰时请戴隔热手套并保持通风。
本产品的 CAS 号、分子式和分子量是多少?
本产品的 CAS 号为 1222102-51-3,分子式为 C19H26F3N3O3?(C4H6O6),分子量为 401.4215009 g/mol。
如何获取批次专用COA?
每个订单都会随附分析证书(COA),您也可以从账户订单历史中下载。如需订购前的COA,请联系您的客户代表,或使用PDP上的"申请COA"按钮——我们将提供代表性批次的COA。